Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best
- PMID: 28819587
- PMCID: PMC5557030
- DOI: 10.21037/tcr.2016.12.39
Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best
Conflict of interest statement
Conflicts of Interest: Dr. Graham is a paid consultant and has received research funding from RedHill Biopharma regarding novel H. pylori therapies and is a consultant to BioGaia regarding use of probiotics for H. pylori infections. Professor Yamaoka has no conflicts of interest to declare.
Figures
Comment on
-
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18. Lancet. 2016. PMID: 27769562 Clinical Trial.
References
-
- Liou JM, Fang YJ, Chen CC, et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388:2355–65. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources